Marshall Fordyce Sells 17,500 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 17,500 shares of the company’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $46.94, for a total value of $821,450.00. Following the sale, the chief executive officer now owns 85,942 shares of the company’s stock, valued at approximately $4,034,117.48. This represents a 16.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, October 23rd, Marshall Fordyce sold 19,375 shares of Vera Therapeutics stock. The stock was sold at an average price of $40.39, for a total value of $782,556.25.
• On Wednesday, October 9th, Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock. The stock was sold at an average price of $38.24, for a total value of $597,500.00.
• On Wednesday, September 25th, Marshall Fordyce sold 23,125 shares of Vera Therapeutics stock. The stock was sold at an average price of $46.05, for a total value of $1,064,906.25.

Vera Therapeutics Trading Down 2.3 %

NASDAQ:VERA traded down $1.06 on Friday, hitting $44.05. The stock had a trading volume of 540,987 shares, compared to its average volume of 875,890. The business’s fifty day moving average is $44.94 and its 200 day moving average is $40.27. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a 52 week low of $14.08 and a 52 week high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.21). On average, sell-side analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of VERA. Cetera Advisors LLC bought a new stake in Vera Therapeutics during the first quarter worth $235,000. William Marsh Rice University bought a new stake in Vera Therapeutics during the second quarter valued at $593,000. EFG Asset Management North America Corp. boosted its stake in Vera Therapeutics by 204.0% during the second quarter. EFG Asset Management North America Corp. now owns 31,444 shares of the company’s stock valued at $1,137,000 after buying an additional 21,101 shares during the period. Bank of New York Mellon Corp boosted its stake in Vera Therapeutics by 6.3% during the second quarter. Bank of New York Mellon Corp now owns 165,322 shares of the company’s stock valued at $5,981,000 after buying an additional 9,854 shares during the period. Finally, Legato Capital Management LLC bought a new stake in Vera Therapeutics during the second quarter worth about $273,000. Institutional investors own 99.21% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wells Fargo & Company assumed coverage on Vera Therapeutics in a research note on Thursday, November 21st. They issued an “overweight” rating and a $70.00 price target for the company. Guggenheim increased their price target on Vera Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research note on Monday, October 28th. JPMorgan Chase & Co. raised their target price on Vera Therapeutics from $72.00 to $75.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Wedbush raised their target price on Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $107.00 target price on shares of Vera Therapeutics in a research note on Tuesday, October 1st. One analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $59.22.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.